BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus: Nine of 10 covering firms rate BBOT a buy, with an average 12-month price target of $22.875, despite several recent target cuts.
• BBOT shares have fallen sharply, opening at $4.95 after a 10.3% decline and near its 52-week low of $4.90. The stock remains well below its 50- and 200-day moving averages of roughly $8.66.
• Institutional ownership stands at 54.89%, with several hedge funds adding or initiating positions. The company reported a quarterly loss of $705.20 per share, while analysts expect a full-year loss of $2.79 per share.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $22.8750.

A number of analysts have recently issued reports on BBOT shares. Stifel Nicolaus dropped their price objective on shares of BridgeBio Oncology Therapeutics from $23.00 to $15.00 and set a "buy" rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered their price target on BridgeBio Oncology Therapeutics from $25.00 to $23.00 and set an "overweight" rating on the stock in a research report on Friday. Wall Street Zen lowered BridgeBio Oncology Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday. Raymond James Financial cut their price objective on BridgeBio Oncology Therapeutics from $24.00 to $22.00 and set an "outperform" rating for the company in a report on Wednesday. Finally, Wedbush reiterated an "outperform" rating and set a $25.00 price objective on shares of BridgeBio Oncology Therapeutics in a research report on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BBOT. Opaleye Management Inc. boosted its stake in shares of BridgeBio Oncology Therapeutics by 1,213.8% in the 2nd quarter. Opaleye Management Inc. now owns 700,000 shares of the company's stock valued at $5,334,000 after purchasing an additional 646,718 shares in the last quarter. Granahan Investment Management LLC bought a new stake in BridgeBio Oncology Therapeutics in the first quarter worth $2,068,000. Catalio Capital Management LP bought a new stake in shares of BridgeBio Oncology Therapeutics in the 4th quarter valued at about $5,142,000. Armistice Capital LLC increased its stake in BridgeBio Oncology Therapeutics by 142.7% in the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company's stock worth $12,520,000 after purchasing an additional 588,000 shares during the period. Finally, BIT Capital GmbH bought a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter worth approximately $313,000. 54.89% of the stock is currently owned by institutional investors.

BridgeBio Oncology Therapeutics Trading Down 10.3%

BBOT stock opened at $4.95 on Friday. The company's 50 day moving average is $8.66 and its 200 day moving average is $8.67. The stock has a market cap of $396.84 million, a price-to-earnings ratio of -1.79 and a beta of 0.38. BridgeBio Oncology Therapeutics has a 1-year low of $4.90 and a 1-year high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that BridgeBio Oncology Therapeutics will post -2.79 EPS for the current fiscal year.

More BridgeBio Oncology Therapeutics News

Here are the key news stories impacting BridgeBio Oncology Therapeutics this week:

• Positive Sentiment: JPMorgan maintained an “overweight” rating while lowering its price target from $25 to $23. Even after the reduction, the target implies substantial potential upside from the recent $4.95 share price. JPMorgan price target update
• Positive Sentiment: Wedbush reiterated its “outperform” rating, signaling that it continues to see meaningful value in BridgeBio Oncology Therapeutics despite the recent selloff. Wedbush reiterates outperform rating
• Neutral Sentiment: The company is narrowing its KRAS strategy. BridgeBio Oncology Therapeutics is focusing its development efforts on a more targeted subset of KRAS-related cancer opportunities. The approach could improve capital allocation and differentiation, but it also increases dependence on a narrower group of clinical programs. BridgeBio Oncology Therapeutics bets on a narrower KRAS strategy
• Negative Sentiment: Analyst downgrades drove renewed selling. Leerink Partners issued a pessimistic forecast, while Wall Street Zen lowered the stock to “strong sell.” These actions have weakened investor sentiment toward the company’s valuation and clinical prospects. Leerink Partners forecast Wall Street Zen strong sell downgrade
• Negative Sentiment: BBOT reached a new 52-week low following the downgrades, reinforcing technical and momentum concerns. The stock’s decline of more than 10% in the recent session occurred alongside unusually heavy trading volume. BridgeBio Oncology Therapeutics new 52-week low Why BBOT stock declined

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.